tiprankstipranks
Advertisement
Advertisement

VIR Stock Latest News

Alec Stranahan Reiterates Buy on Vir Biotechnology, Sees Undervalued Pipeline with Unchanged $16 Price Target
RatingsAlec Stranahan Reiterates Buy on Vir Biotechnology, Sees Undervalued Pipeline with Unchanged $16 Price Target
3d ago
VIR
Vir Biotechnology Announces Board Changes and Shareholder Approvals
PremiumCompany Announcements
Vir Biotechnology Announces Board Changes and Shareholder Approvals
6d ago
8K
VIR
Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial
PremiumThe Fly
Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial
16d ago
VIR
Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley
PremiumThe Fly
Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley
26d ago
VIR
Analyst Maintains Buy Rating and $20 Price Target on Vir, Citing Strengthened Oncology Franchise and Favorable Hepatitis Delta Outlook
PremiumRatings
Analyst Maintains Buy Rating and $20 Price Target on Vir, Citing Strengthened Oncology Franchise and Favorable Hepatitis Delta Outlook
27d ago
VIR
Vir Biotechnology Signals Momentum in Latest Earnings Call
PremiumCompany AnnouncementsVir Biotechnology Signals Momentum in Latest Earnings Call
27d ago
VIR
Vir Biotechnology Earns Buy Rating on Advancing Oncology and Hepatitis Delta Pipelines and Strong Cash Runway Into 2028
Premium
Ratings
Vir Biotechnology Earns Buy Rating on Advancing Oncology and Hepatitis Delta Pipelines and Strong Cash Runway Into 2028
28d ago
VIR
Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year
Premium
The Fly
Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year
28d ago
VIR
Analyst Reiterates Buy on Vir Biotechnology, Citing Best-in-Class HDV Profile and Maintaining $18 Price Target
PremiumRatings
Analyst Reiterates Buy on Vir Biotechnology, Citing Best-in-Class HDV Profile and Maintaining $18 Price Target
1M ago
VIR
Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update
PremiumCompany Announcements
Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update
1M ago
VIR
Vir Biotechnology closes global collaboration agreement with Astellas Pharma
PremiumThe Fly
Vir Biotechnology closes global collaboration agreement with Astellas Pharma
2M ago
SNY
VIR
Vir Biotechnology announces first patient dosed in Phase 1 trial of VIR-5500
PremiumThe Fly
Vir Biotechnology announces first patient dosed in Phase 1 trial of VIR-5500
2M ago
VIR
Vir Biotechnology Announces Upcoming Chief Medical Officer Transition
PremiumCompany AnnouncementsVir Biotechnology Announces Upcoming Chief Medical Officer Transition
2M ago
8K
VIR
Vir Biotechnology Names CEO Marianne De Backer as President
Premium
Company Announcements
Vir Biotechnology Names CEO Marianne De Backer as President
3M ago
8K
VIR
Vir Biotechnology price target raised to $20 from $15 at H.C. Wainwright
Premium
The Fly
Vir Biotechnology price target raised to $20 from $15 at H.C. Wainwright
3M ago
VIR
Vir Biotechnology Raises Capital Through Public Stock Offering
PremiumCompany Announcements
Vir Biotechnology Raises Capital Through Public Stock Offering
3M ago
8K
VIR
Vir Biotechnology Announces Significant Common Stock Offering
PremiumCompany Announcements
Vir Biotechnology Announces Significant Common Stock Offering
3M ago
8K
VIR
Vir Biotechnology 17.65M share Secondary priced at $8.50
PremiumThe Fly
Vir Biotechnology 17.65M share Secondary priced at $8.50
3M ago
VIR
TheStreet Pro: Four Stocks that Will Win Despite “Irrational Panic” over AI
PremiumMarket News
TheStreet Pro: Four Stocks that Will Win Despite “Irrational Panic” over AI
3M ago
COF
VIR
Vir Biotechnology’s Call Highlights Astellas Deal, VIR-5500 Momentum
PremiumCompany AnnouncementsVir Biotechnology’s Call Highlights Astellas Deal, VIR-5500 Momentum
3M ago
VIR
Vir Biotechnology announces $200M public offering of common stock
Premium
The Fly
Vir Biotechnology announces $200M public offering of common stock
3M ago
VIR
Vir Biotechnology price target raised to $30 from $26 at Barclays
Premium
The Fly
Vir Biotechnology price target raised to $30 from $26 at Barclays
3M ago
VIR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >